HRP20201815T1 - Nukleinske kiseline za liječenje alergija - Google Patents

Nukleinske kiseline za liječenje alergija Download PDF

Info

Publication number
HRP20201815T1
HRP20201815T1 HRP20201815TT HRP20201815T HRP20201815T1 HR P20201815 T1 HRP20201815 T1 HR P20201815T1 HR P20201815T T HRP20201815T T HR P20201815TT HR P20201815 T HRP20201815 T HR P20201815T HR P20201815 T1 HRP20201815 T1 HR P20201815T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
seq
acid molecule
treatment
pharmaceutical composition
Prior art date
Application number
HRP20201815TT
Other languages
English (en)
Croatian (hr)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of HRP20201815T1 publication Critical patent/HRP20201815T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HRP20201815TT 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija HRP20201815T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies
EP12878776.9A EP2861240B1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
HRP20201815T1 true HRP20201815T1 (hr) 2021-02-19

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201815TT HRP20201815T1 (hr) 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija

Country Status (20)

Country Link
US (3) US9744230B2 (enExample)
EP (2) EP3808361A1 (enExample)
JP (1) JP5807994B2 (enExample)
KR (2) KR102386481B1 (enExample)
CN (2) CN107937423A (enExample)
AU (3) AU2012382406B2 (enExample)
BR (1) BR112014031327B1 (enExample)
CA (1) CA2876824C (enExample)
CY (1) CY1123769T1 (enExample)
DK (1) DK2861240T3 (enExample)
ES (1) ES2831723T3 (enExample)
HR (1) HRP20201815T1 (enExample)
HU (1) HUE052481T2 (enExample)
IL (4) IL236174B (enExample)
LT (1) LT2861240T (enExample)
PL (1) PL2861240T3 (enExample)
PT (1) PT2861240T (enExample)
RS (1) RS61098B1 (enExample)
SI (1) SI2861240T1 (enExample)
WO (1) WO2013187906A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
HUE052481T2 (hu) 2012-06-15 2021-04-28 Immunomic Therapeutics Inc Nukleinsavak, allergiák kezelésére
DK2914286T3 (da) 2012-10-30 2021-11-08 Aravax Pty Ltd Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CN106459994A (zh) * 2014-06-23 2017-02-22 免疫治疗有限公司 用于治疗花生过敏的核酸
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
JP6697562B2 (ja) 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018195527A1 (en) * 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
US11382934B2 (en) 2017-07-18 2022-07-12 Before Brands, Inc. Methods for making mixed allergen compositions
WO2019194656A1 (ko) * 2018-04-06 2019-10-10 (주)에스엘에스바이오 신규한 면역글로불린 e의 에피토프, 그와 결합하는 항체 및 상기 항체를 포함하는 시료 중 면역글로불린 e를 분석하기 위한 키트
CA3099495A1 (en) * 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating mite allergy
WO2019216396A1 (ja) * 2018-05-11 2019-11-14 アステラス製薬株式会社 甲殻類アレルギー治療のための核酸
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
CA3127337A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
JP7266700B2 (ja) * 2019-03-13 2023-04-28 プソマーゲン， インコーポレイテッド アレルギー治療のためのエピトープベースアプローチ及びクローン病のための阻害薬
EP4333807A1 (en) * 2021-05-04 2024-03-13 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
AU2022321126A1 (en) * 2021-08-06 2024-02-29 Kao Corporation Nucleic acid structure utilizing snare
FI20237105A1 (en) 2023-05-29 2024-11-30 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic action and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AU5668194A (en) * 1992-11-12 1994-06-08 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
JPH11507840A (ja) 1995-12-29 1999-07-13 ユニバーシティ オブ アーカンソー ピーナッツアレルゲンおよび方法
DE69737659T2 (de) 1996-06-14 2007-12-27 Meiji Dairies Corp. Peptide aus t-zellepitopen
EP1278550A4 (en) * 2000-04-07 2004-05-12 Univ California SYNERGISTIC IMPROVEMENTS OF POLYNUCLEOTIDE VACCINE
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
ES2404689T3 (es) 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
WO2006099574A2 (en) * 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
US20090304738A1 (en) 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
JPWO2007024026A1 (ja) * 2005-08-25 2009-03-05 明石　満 Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
WO2010029317A2 (en) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions
HUE052481T2 (hu) 2012-06-15 2021-04-28 Immunomic Therapeutics Inc Nukleinsavak, allergiák kezelésére
US11826423B2 (en) * 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018195527A1 (en) * 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs

Also Published As

Publication number Publication date
CN107937423A (zh) 2018-04-20
LT2861240T (lt) 2021-01-25
US20220081474A1 (en) 2022-03-17
AU2018200625B2 (en) 2019-09-19
BR112014031327A2 (pt) 2017-06-27
CA2876824A1 (en) 2013-12-19
IL270261B (en) 2021-03-25
AU2012382406A2 (en) 2015-04-16
CY1123769T1 (el) 2022-05-27
RS61098B1 (sr) 2020-12-31
US9744230B2 (en) 2017-08-29
CN104519896A (zh) 2015-04-15
KR102107646B1 (ko) 2020-05-08
US20160271245A1 (en) 2016-09-22
AU2018200625A1 (en) 2018-02-15
PT2861240T (pt) 2020-11-09
IL236174B (en) 2019-11-28
EP2861240A1 (en) 2015-04-22
KR20200047792A (ko) 2020-05-07
EP2861240B1 (en) 2020-09-09
HUE052481T2 (hu) 2021-04-28
JP2015521467A (ja) 2015-07-30
AU2019250227B2 (en) 2021-10-21
PL2861240T3 (pl) 2021-07-05
EP3808361A1 (en) 2021-04-21
CA2876824C (en) 2020-07-21
SI2861240T1 (sl) 2021-04-30
AU2012382406A1 (en) 2014-12-18
KR102386481B1 (ko) 2022-04-14
US20180009857A1 (en) 2018-01-11
DK2861240T3 (da) 2020-09-28
JP5807994B2 (ja) 2015-11-10
KR20150032286A (ko) 2015-03-25
IL270262A (en) 2019-12-31
EP2861240A4 (en) 2016-03-16
WO2013187906A1 (en) 2013-12-19
ES2831723T3 (es) 2021-06-09
IL236174A0 (en) 2015-01-29
AU2012382406B2 (en) 2017-12-07
US10072053B2 (en) 2018-09-11
CN104519896B (zh) 2017-11-10
BR112014031327B1 (pt) 2022-02-01
IL270260B (en) 2020-08-31
AU2019250227A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
HRP20201815T1 (hr) Nukleinske kiseline za liječenje alergija
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
EA201200515A1 (ru) Полипептиды и их применение
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
UA107571C2 (xx) Фармацевтична композиція
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR112015003947A8 (pt) Proteínas de fusão e métodos para tratar, prevenir ou melhorar dor
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
MX358762B (es) Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b